Renaissance Technologies (RenTech)'s ACRS Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 817,531 shares of Aclaris Therapeutics, Inc. (ACRS) worth $4.32 M, representing 0.01% of the portfolio. First purchased in 2016-Q4, this long-term strategic position has been held for 35 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in ACRS, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2019, adding 1.27 M shares. Largest reduction occurred in Q2 2024, reducing 751,200 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Aclaris Therapeutics (ACRS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Aclaris Therapeutics (ACRS) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +314,900 | Add 62.65% | 817,531 | $5.29 |
| Q1 2026 | -622,700 | Reduce 55.33% | 502,631 | $3.75 |
| Q4 2025 | -494,400 | Reduce 30.52% | 1.13 M | $3.01 |
| Q3 2025 | +154,953 | Add 10.58% | 1.62 M | $1.90 |
| Q2 2025 | +513,384 | Add 53.96% | 1.46 M | $1.42 |
| Q1 2025 | +100,875 | Add 11.86% | 951,394 | $1.53 |
| Q4 2024 | -520,181 | Reduce 37.95% | 850,519 | $2.48 |
| Q3 2024 | +448,500 | Add 48.63% | 1.37 M | $1.15 |
| Q2 2024 | -751,200 | Reduce 44.89% | 922,200 | $1.10 |
| Q1 2024 | -73,032 | Reduce 4.18% | 1.67 M | $1.24 |
| Q4 2023 | +1.1 M | Add 169.66% | 1.75 M | $1.05 |
| Q3 2023 | -321,900 | Reduce 33.20% | 647,652 | $6.85 |
| Q2 2023 | -282,600 | Reduce 22.57% | 969,552 | $0.01 |
| Q1 2023 | +130,400 | Add 11.62% | 1.25 M | $0.01 |
| Q4 2022 | -63,426 | Reduce 5.35% | 1.12 M | $0.02 |
| Q3 2022 | -144,500 | Reduce 10.87% | 1.19 M | $15.74 |
| Q2 2022 | -127,900 | Reduce 8.77% | 1.33 M | $13.96 |
| Q1 2022 | -219,300 | Reduce 13.08% | 1.46 M | $17.24 |
| Q4 2021 | -344,000 | Reduce 17.02% | 1.68 M | $14.54 |
| Q3 2021 | -411,000 | Reduce 16.90% | 2.02 M | $18.00 |
| Q2 2021 | -554,600 | Reduce 18.57% | 2.43 M | $17.56 |
| Q1 2021 | -281,700 | Reduce 8.62% | 2.99 M | $25.20 |
| Q4 2020 | -165,212 | Reduce 4.81% | 3.27 M | $6.47 |
| Q3 2020 | +153,550 | Add 4.68% | 3.43 M | $2.57 |
| Q2 2020 | +104,204 | Add 3.28% | 3.28 M | $1.62 |
| Q1 2020 | +393,339 | Add 14.14% | 3.18 M | $1.04 |
| Q4 2019 | +813,581 | Add 41.33% | 2.78 M | $1.89 |
| Q3 2019 | +1.27 M | Add 181.41% | 1.97 M | $1.08 |
| Q2 2019 | +272,200 | Add 63.69% | 699,580 | $2.19 |
| Q1 2019 | +331,700 | Add 346.68% | 427,380 | $5.99 |
| Q4 2018 | +95,680 | New Buy | 95,680 | $7.39 |
| Q3 2017 | -28,900 | Sold Out | 0 | $0.00 |
| Q2 2017 | -59,179 | Reduce 67.19% | 28,900 | $27.13 |
| Q1 2017 | -86,521 | Reduce 49.55% | 88,079 | $29.83 |
| Q4 2016 | +174,600 | New Buy | 174,600 | $27.14 |
Renaissance Technologies (RenTech)'s Aclaris Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Aclaris Therapeutics, Inc. (ACRS) in Q4 2016, acquiring 174,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Aclaris Therapeutics, Inc. (ACRS) for 35 quarters since Q4 2016.
Renaissance Technologies (RenTech)'s largest addition to Aclaris Therapeutics, Inc. (ACRS) was in Q3 2019, adding 1,968,716 shares worth $2.13 M.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 817,531 shares of Aclaris Therapeutics, Inc. (ACRS), valued at approximately $4.32 M.
As of the Q2 2026 filing, Aclaris Therapeutics, Inc. (ACRS) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Aclaris Therapeutics, Inc. (ACRS) was 3,433,390 shares, as reported at the end of Q3 2020.